2qcg
From Proteopedia
| Line 2: | Line 2: | ||
caption="2qcg, resolution 1.75Å" /> | caption="2qcg, resolution 1.75Å" /> | ||
'''Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase bound to 5-bromo-UMP'''<br /> | '''Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase bound to 5-bromo-UMP'''<br /> | ||
| + | |||
| + | ==Overview== | ||
| + | UMP synthase (UMPS) catalyzes the last two steps of de novo pyrimidine, nucleotide synthesis and is a potential cancer drug target. The C-terminal, domain of UMPS is orotidine-5'-monophosphate decarboxylase (OMPD), a, cofactor-less yet extremely efficient enzyme. Studies of OMPDs from, micro-organisms led to the proposal of several noncovalent decarboxylation, mechanisms via high-energy intermediates. We describe nine crystal, structures of human OMPD in complex with substrate, product, and, nucleotide inhibitors. Unexpectedly, simple compounds can replace the, natural nucleotides and induce a closed conformation of OMPD, defining a, tripartite catalytic site. The structures outline the requirements drugs, must meet to maximize therapeutic effects and minimize cross-species, activity. Chemical mimicry by iodide identified a CO(2) product binding, site. Plasticity of catalytic residues and a covalent OMPD-UMP complex, prompt a reevaluation of the prevailing decarboxylation mechanism in favor, of covalent intermediates. This mechanism can also explain the observed, catalytic promiscuity of OMPD. | ||
| + | |||
| + | ==Disease== | ||
| + | Known disease associated with this structure: Oroticaciduria OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=258900 258900]] | ||
==About this Structure== | ==About this Structure== | ||
| - | 2QCG is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=5BU:'>5BU</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Orotidine-5'-phosphate_decarboxylase Orotidine-5'-phosphate decarboxylase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=4.1.1.23 4.1.1.23] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2QCG OCA]. | + | 2QCG is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=5BU:'>5BU</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Orotidine-5'-phosphate_decarboxylase Orotidine-5'-phosphate decarboxylase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=4.1.1.23 4.1.1.23] Known structural/functional Sites: <scene name='pdbsite=AC1:5bu+Binding+Site+For+Residue+A+1'>AC1</scene> and <scene name='pdbsite=AC2:5bu+Binding+Site+For+Residue+B+2'>AC2</scene>. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2QCG OCA]. |
| + | |||
| + | ==Reference== | ||
| + | Structures of the human orotidine-5'-monophosphate decarboxylase support a covalent mechanism and provide a framework for drug design., Wittmann JG, Heinrich D, Gasow K, Frey A, Diederichsen U, Rudolph MG, Structure. 2008 Jan;16(1):82-92. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=18184586 18184586] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Orotidine-5'-phosphate decarboxylase]] | [[Category: Orotidine-5'-phosphate decarboxylase]] | ||
| Line 16: | Line 25: | ||
[[Category: ump synthase]] | [[Category: ump synthase]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Feb 13 08:18:20 2008'' |
Revision as of 06:18, 13 February 2008
|
Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase bound to 5-bromo-UMP
Contents |
Overview
UMP synthase (UMPS) catalyzes the last two steps of de novo pyrimidine, nucleotide synthesis and is a potential cancer drug target. The C-terminal, domain of UMPS is orotidine-5'-monophosphate decarboxylase (OMPD), a, cofactor-less yet extremely efficient enzyme. Studies of OMPDs from, micro-organisms led to the proposal of several noncovalent decarboxylation, mechanisms via high-energy intermediates. We describe nine crystal, structures of human OMPD in complex with substrate, product, and, nucleotide inhibitors. Unexpectedly, simple compounds can replace the, natural nucleotides and induce a closed conformation of OMPD, defining a, tripartite catalytic site. The structures outline the requirements drugs, must meet to maximize therapeutic effects and minimize cross-species, activity. Chemical mimicry by iodide identified a CO(2) product binding, site. Plasticity of catalytic residues and a covalent OMPD-UMP complex, prompt a reevaluation of the prevailing decarboxylation mechanism in favor, of covalent intermediates. This mechanism can also explain the observed, catalytic promiscuity of OMPD.
Disease
Known disease associated with this structure: Oroticaciduria OMIM:[258900]
About this Structure
2QCG is a Single protein structure of sequence from Homo sapiens with as ligand. Active as Orotidine-5'-phosphate decarboxylase, with EC number 4.1.1.23 Known structural/functional Sites: and . Full crystallographic information is available from OCA.
Reference
Structures of the human orotidine-5'-monophosphate decarboxylase support a covalent mechanism and provide a framework for drug design., Wittmann JG, Heinrich D, Gasow K, Frey A, Diederichsen U, Rudolph MG, Structure. 2008 Jan;16(1):82-92. PMID:18184586
Page seeded by OCA on Wed Feb 13 08:18:20 2008
